Prostate Cancer: Risk, Diagnosis, and Management

Introduction

Prostate cancer is the most common cancer in men worldwide, and its incidence increases with age. While many cases grow slowly and may not cause harm, others can be aggressive and life-threatening. Understanding risk factors, early signs, diagnostic methods, and treatment options is essential for effective management and improved outcomes.

Epidemiology and Age-Related Risk

Prostate cancer incidence rises steeply with age, with men over 65 at the highest risk. Around six in ten cases are diagnosed in men aged 65 or older, with the median age at diagnosis being 67–68 years.

  • Rare before age 40.
  • Sharp rise after age 50.
  • Nearly 43% of new cases occur between 65–74 years, and another 18% between 75–84 years.

 

This strong association with increasing age underscores prostate cancer as primarily a disease of older men.

Risk Factors

Established Risk Factors

  • Age: The single most significant factor.
  • Family History: Having a first-degree relative with prostate cancer doubles the risk. Risk is higher if multiple relatives are affected or diagnosed at a young age.
  • Ethnicity: Black men have the highest incidence and mortality.
  • Genetics: BRCA1 and BRCA2 mutations, Lynch syndrome, and other inherited genetic changes increase risk.

 

Article content

Lifestyle and Environmental Factors

  • Obesity: Moderately increases risk and is associated with more aggressive disease.
  • Diet: High intake of red meat and dairy, and low intake of fruits and vegetables, may play a role.
  • Lifestyle changes: Sedentary habits and urbanization contribute to rising incidence in developing countries.

 

Prostate Cancer in India

In India, incidence is very low below age 55 but rises sharply after this age, peaking in men over 65. Age-specific incidence rates from cancer registries show:

  • Below 1 per 100,000 in men under 55.
  • Rising to 10–15 per 100,000 in those over 65.

 

Recent trends indicate a gradual rise among men aged 55–64, and to a lesser extent in younger groups (35–44) in large cities, reflecting lifestyle changes. Young-onset prostate cancer, while still rare, is increasing in urban India and often presents at a more advanced stage, with higher mortality due to delayed diagnosis.

Symptoms and Early Detection

Early Stage

Most early prostate cancers cause no symptoms and are detected through screening. When present, symptoms often involve urinary changes:

  • Difficulty starting urination.
  • Weak or interrupted urine flow.
  • Frequent urination, especially at night.
  • Feeling of incomplete bladder emptying.
  • Blood in urine or semen.
  • Painful urination or erectile dysfunction.

 

Article content

These are not specific to cancer and may also occur in benign prostate conditions.

When to Consult a Doctor

Men should seek medical evaluation if urinary symptoms persist, especially if accompanied by:

  • Bone pain.
  • Unexplained weight loss.
  • Erectile dysfunction.

 

Men over 50—or younger men with family history or high risk—should discuss screening with their doctors.

Diagnosis

Initial Evaluation

  • Digital Rectal Exam (DRE): Detects abnormalities in prostate size and texture.
  • Prostate-Specific Antigen (PSA) Test: Elevated levels may indicate cancer but can also occur in benign conditions.

 

Imaging and Biopsy

  • Multiparametric MRI: Identifies suspicious areas for targeted biopsy.
  • Biopsy: Transrectal or transperineal ultrasound-guided sampling is required for confirmation and grading.

 

Staging

Cancer staging determines the extent of disease using:

  • PSMA PET-CT (highly sensitive).
  • Bone scans, CT, and MRI. Staging is crucial for treatment planning.

 

Article content

Biomarkers

Beyond PSA, several biomarkers aid diagnosis and prognosis:

  • PCA3: A urine test highly specific for prostate cancer.
  • AMACR: A tissue marker often positive in biopsy pathology.
  • PTEN loss and TMPRSS2-ERG fusion: Associated with prognosis and therapy response.
  • Emerging biomarkers: Exosomal proteins, microRNAs, and DNA methylation profiles offer potential for precision medicine.

 

Treatment Options

Treatment depends on cancer stage, aggressiveness, and patient health.

Active Surveillance

For low-risk localized cancers, close monitoring avoids or delays treatment. Regular PSA tests, MRIs, and biopsies are done, with curative treatment initiated if disease progresses. This strategy balances effective control with minimizing side effects.

Surgery

Radical Prostatectomy removes the prostate gland and sometimes nearby tissues.

  • Best suited for healthy men with localized cancer.
  • Risks include urinary incontinence and erectile dysfunction.
  • Requires hospitalization but offers excellent long-term control.

 

Radiation Therapy

Radiation destroys cancer cells using external beams (EBRT) or internal sources (brachytherapy).

  • Less risk of urinary incontinence compared to surgery.
  • More likely to cause bowel-related issues.
  • Highly effective for localized disease.

 

Hormone Therapy

Androgen deprivation therapy reduces testosterone, slowing cancer growth. Used for advanced or recurrent disease, often in combination with other treatments.

Chemotherapy

Reserved for advanced or castration-resistant prostate cancer.

Novel Therapies

  • High-Intensity Focused Ultrasound (HIFU).
  • Immunotherapy in selected cases.
  • PARP inhibitors for men with BRCA mutations.
  • PSMA-targeted radioligand therapy for advanced disease.

 

Surgery vs Radiation: Key Comparisons

Both surgery and radiation offer similar long-term survival for localized cancer.

  • Surgery: Higher risk of urinary incontinence and erectile dysfunction but relieves obstruction.
  • Radiation: Fewer urinary side effects but more bowel issues; ED develops gradually over time.
  • Choice depends on cancer stage, patient health, and personal preference.

 

Side Effects of Treatment

Urinary Incontinence

  • After Surgery: Occurs in 6–22% of men, especially older or obese patients. Improves with time; pelvic floor therapy or surgical correction may be required.
  • After Radiation: Less common (<10% at 3 years) but can occur late due to bladder damage.

 

Erectile Dysfunction

  • After Surgery: Very common due to nerve injury; recovery may take up to 18 months. Nerve-sparing techniques and younger age improve outcomes.
  • After Radiation: Gradual onset, with 17–26% affected at 2 years.

 

Bladder Function After Radiotherapy

  • Reduced bladder compliance and capacity.
  • Increased urgency and frequency of urination.
  • Persistent outlet obstruction since the prostate remains in place.
  • Risk of late complications such as urethral stricture and radiation cystitis.

 

Role of PSMA PET in Management

PSMA PET is a breakthrough imaging tool that detects prostate cancer with high sensitivity.

Applications:

  • Accurate staging at diagnosis.
  • Detection of recurrence when PSA rises after treatment.
  • Improved treatment planning with tailored strategies.
  • Lower radiation exposure and fewer inconclusive results compared to CT or bone scans.

 

FDA-approved tracers and global guidelines now endorse PSMA PET as a standard in prostate cancer care.

Advances in Prostate Cancer Treatment

Recent innovations have improved outcomes and reduced side effects:

  • Robotic-assisted surgery offers precision with faster recovery.
  • Advanced radiotherapy techniques minimize collateral damage.
  • Novel systemic therapies (androgen receptor inhibitors, PARP inhibitors).
  • PSMA-targeted radioligand therapy for advanced disease.
  • Immunotherapy trials show promise in early-stage and aggressive cases.

 

These advances reflect a move toward personalized and targeted treatment strategies.

Article content

Prognosis

Prostate cancer prognosis depends on stage, grade, and health at diagnosis.

  • Localized disease: Excellent, with nearly 100% 5-year survival.
  • Advanced disease: Poorer, with around 38% 5-year survival in metastatic cases.

 

Other important prognostic factors include:

  • Gleason score
  • PSA levels
  • Tumour volume
  • Surgical margins
  • Molecular markers (p53, Ki-67)

 

Younger men and those in good overall health have better outcomes. Despite many cases being slow-growing, risk stratification is essential to tailor therapy.

Conclusion

Prostate cancer is predominantly a disease of older men but is rising in younger age groups in India and worldwide due to lifestyle changes and better detection. Early diagnosis through PSA, DRE, and advanced imaging like PSMA PET allows timely and tailored treatment. With evolving therapies—ranging from active surveillance to precision medicine—outcomes are improving. Individualized care remains the cornerstone of balancing cancer control with quality of life.